Chemomab Therapeutics Ltd. (CMMB)

$3.03

+0.03 (+1.00%)
Rating:
Recommendation:
-
Symbol CMMB
Price $3.03
Beta 0.000
Volume Avg. 0.05M
Market Cap 34.556M
Shares () -
52 Week Range 2.53-27.92
1y Target Est -
DCF Unlevered CMMB DCF ->
DCF Levered CMMB LDCF ->
ROE -25.18% Sell
ROA -26.05% Sell
Operating Margin -
Debt / Equity 6.50% Neutral
P/E -
P/B 0.60 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CMMB news


Dr. Frank G. Haluska
Healthcare
Biotechnology
NASDAQ Capital Market

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.